Jurjen Versluis

Jurjen Versluis is a Researcher in the Department of Hematology at Erasmus MC, Rotterdam, the Netherlands, focusing on acute leukemias with emphasis on transplantation outcomes and risk stratification.

His research spans critical areas in hematologic malignancies:

• Allogeneic hematopoietic cell transplantation for AML and ALL
• ELN 2022 cytogenetic risk subgroup analysis
• Remission dynamics and conditioning regimens
• Real-time cancer registry data validation
• Survival metrics in high-risk leukemia

Recent 2025 publications reveal collaborative trends through the EBMT ALWP, emphasizing registry-based validation studies, innovative trial designs for rare cancers, and re-evaluation of adverse-risk transplantation protocols. His work bridges clinical practice with data infrastructure improvements across European centers.

No scientific awards were documented in the source material.

Details regarding student advising and grant funding remain unspecified in the available information.

Dr. Versluis actively contributes to the EBMT ALWP (Acute Leukemia Working Party), participating in multinational studies that analyze transplantation outcomes, induction therapy impacts, and risk-adapted treatment strategies for leukemia patients.